Celldex Therapeutics Announces Upcoming Data Presentations

HAMPTON, N.J., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple Company drug development programs will be the subject of presentations at upcoming medical and scientific conferences.

Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting & Pre-Conference Programs (SITC 2019), November 6-10 in National Harbor, Maryland

• CDX-1140: The abstract (Abstract ID: P827) entitled, “Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers” will be presented in a poster presentation by Rachel Sanborn, MD, Co-director of the Thoracic Oncology Program and Leader of the Phase 1 Trials Program at Providence Cancer Institute and a lead investigator in this study, on Friday, November 8, 2019 from 8:00 am to 8:00 pm ET. Michael Yellin, MD, Vice President of Clinical Science at Celldex will also present a talk entitled CD40: A Target for Systemic Immune Modulation at the Workshop on Intratumoral Immunomodulation on Thursday, November 7, 2019 at 3:00 pm ET.
• CDX-527: The abstract (Abstract ID: P700) entitled, “Combining CD27 costimulation and PD-1 blockade into a bispecific antibody improves T cell activation and anti-tumor activity over combination of individual antibodies” will be presented in a poster presentation by Tibor Keler, PhD, Executive Vice President and Chief Scientific Officer at Celldex, on Saturday, November 9, 2019 from 8:00 am to 8:00 pm ET. This program will also be highlighted in a short talk by Dr. Keler during the preconference program session “Novel Multi-Targeted Therapeutic Platforms” on Wednesday, November 6, 2019 at 4:45 pm ET.

American College of Allergy, Asthma & Immunology Annual Scientific Meeting, November 7-11 in Houston, Texas

• CDX-0159: The abstract (Abstract ID: 8071) entitled, “CDX-0159, An Anti-KIT Monoclonal Antibody, As A Modulator of Mast Cell-related Diseases” has been accepted for presentation by Richard Gedrich, PhD, Executive Director of Translational Medicine at Celldex, in the Distinguished Industry Oral Abstract Session on Saturday, November 9, 2019 at 4:35 pm CT.

Copies of these presentations will be made available on the after presentation.

About Celldex Therapeutics, Inc.

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes immunotherapies and other targeted biologics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. Visit .

Forward Looking Statement

This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates; our ability to obtain additional capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; our ability to maintain compliance with Nasdaq listing requirements; our ability to realize the cost benefits of consolidating our office and laboratory space and to retain key personnel after that consolidation; our ability to realize the anticipated benefits from the acquisition of Kolltan; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical and commercial grade materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact

Sarah Cavanaugh

Senior Vice President, Corporate Affairs & Administration

Celldex Therapeutics, Inc.

(781) 433-3161